Rallybio Corp (NASDAQ:RLYB) has a beta value of -1.16 and has seen 1.43 million shares traded in the last trading session. The company, currently valued at $17.23M, closed the last trade at $0.41 per share which meant it lost -$0.01 on the day or -1.43% during that session. The RLYB stock price is -275.61% off its 52-week high price of $1.54 and 46.34% above the 52-week low of $0.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 16.03 million shares traded. The 3-month trading volume is 2.78 million shares.
The consensus among analysts is that Rallybio Corp (RLYB) is Buy stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.25.
Rallybio Corp (NASDAQ:RLYB) trade information
Sporting -1.43% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RLYB stock price touched $0.41 or saw a rise of 20.73%. Year-to-date, Rallybio Corp shares have moved -71.05%, while the 5-day performance has seen it change -19.05%. Over the past 30 days, the shares of Rallybio Corp (NASDAQ:RLYB) have changed 25.38%. Short interest in the company has seen 0.33 million shares shorted with days to cover at 1.3.
Rallybio Corp (RLYB) estimates and forecasts
The company’s shares have lost -55.96% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -68.55%.
Year-ago sales stood 299k and 299k respectively for this quarter and the next, and analysts expect sales will shrink by -100.00% for the current quarter and -68.55% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -19.41% over the past 5 years.
RLYB Dividends
Rallybio Corp is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Rallybio Corp (NASDAQ:RLYB)’s Major holders
Insiders own 4.16% of the company shares, while shares held by institutions stand at 76.90% with a share float percentage of 80.24%. Investors are also buoyed by the number of investors in a company, with Rallybio Corp having a total of 48.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 4.19 million shares worth more than $5.62 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 10.288% of shares outstanding.
The other major institutional holder is JOHNSON & JOHNSON, with the holding of over 3.64 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.87 million and represent 8.9184% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are abrdn Healthcare Investors and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.81% shares in the company for having 755.08 shares of worth $0.31 million while later fund manager owns 649.66 shares of worth $0.27 million as of Mar 31, 2025 , which makes it owner of about 1.56% of company’s outstanding stock.
